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Abstract The winter flounder antifreeze protein (AFP) intron
contains a liver-specific enhancer (Element B) which was shown
earlier to bind CCAAT/enhancer binding protein (C/EBP)K. In
contrast, as demonstrated in the present studies, the intron of the
skin-type AFP gene acted as a ubiquitous enhancer and
contained a TA insertion at similar region to Element B
(Element S) which destroyed its interaction with C/EBPK.
Furthermore, a TA insertion of Element B by site-directed
mutagenesis decreased its liver enhancer activity. The presence or
absence of C/EBPK binding motifs in Element B and Element S,
respectively, may provide a mechanism for their differential
expression.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The winter £ounder, Pleuronectes americanus, is a common
teleost inhabiting the shallow seawater of the Atlantic coast of
North America. It frequently encounters seawater tempera-
tures below 30.8‡C during the winter months. To avoid freez-
ing to death, the animal produces antifreeze proteins (AFPs)
to lower its plasma freezing temperature below that of the
surrounding environment. These AFPs are able to bind to
ice crystals, and inhibit ice crystal growth [1]. The winter
£ounder AFPs have been extensively characterized (for re-
view, see [2]). These AFPs are synthesized from a multigene
family of approximately 80 copies and occur in several iso-
forms. The most abundant AFP component (HPLC-6) found
in the serum is a helical polypeptide of 37 amino acids rich in
alanine, and its three-dimensional structure has been eluci-
dated [3,4].
More recently, our laboratories have demonstrated that
there are two distinct classes of AFPs in the winter £ounder.
HPLC-6 and several other AFPs isolated from the sera are
produced individually from liver as a preproAFP encoded by
the liver-type AFP genes. The second type of polypeptides, the
skin-type AFPs, lack both the Pre and Pro sequences and are
synthesized from a di¡erent set of AFP genes as mature pro-
teins primarily in skin and other external tissues. Further-
more, these two sets of AFP genes are found to be di¡eren-
tially regulated by the environment and somatotropin [5].
Thus, the £ounder is the only ¢sh species presently known
to contain both the extracellular, liver-type AFPs and the
intracellular, skin-type AFPs [6].
The presence of two distinct AFPs within a single species of
animal has raised many important questions on the relative
role of these proteins in freezing protection, their evolutionary
relationships, as well as their regulationary mechanisms. The
tissue-speci¢c expression of the liver-type AFPs is conferred
by an enhancer element, Element B (from +303 to +322), in
the only intron of the AFP gene [7]. Element B contains DNA
binding motifs for CCAAT/enhancer binding protein (C/
EBP)K, a liver enriched transcription factor, and a novel
AP-1 binding protein, tentatively designated as the Antifreeze
Enhancer binding Protein (AEP). The present investigation
was undertaken to examine the molecular mechanisms con-
trolling the expression of the skin-type AFP genes which are
expressed in many tissues and in particular the contribution of
C/EBPK, if any, in activating these genes.
2. Materials and methods
2.1. Plasmid construction
The F2 genomic clone encoding the skin-type AFP gene [8] was
kindly provided by Dr. P. Davies, Queen’s University. To generate
constructs of the skin-type intron with chloramphenicol acetyltrans-
ferase (CAT) reporter gene, the 2.3-kbp PstI fragment of the F2
genomic clone was subcloned into pBluescript. The 750-bp PstI/Hin-
cII intron fragment from the 2.3-kbp fragment was further puri¢ed
and ligated to the PstI site of the fAFP-CAT construct which contains
the basic promoter sequence from 3143 to +32 of 2A-7b AFP gene
upstream of pBLCAT3 [7]. Constructs with the 750-bp F2 intron
fragment in forward and reverse orientation were designated as
F2In-fAFP-CAT and RF2In-fAFP-CAT, respectively. The In-fARP-
CAT construct, which contains the complete 2A-7b liver-type intron,
was generated as described previously [7]. The constructs were veri¢ed
by DNA sequencing.
2.2. Cell culture and transient expression assay
Newborn rat keratinocytes (NBRK) were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% calf se-
rum and 2.5% fetal bovine serum, HeLa cells in minimum essential
medium (MEM) with 10% calf serum and HepG2 cells in MEM with
10% fetal bovine serum. DNA was transfected into cells by calcium
phosphate precipitation method [9] and cells were harvested 48 h after
transfection. The CAT assay was performed using a highly sensitive
mixed-phase assay [10,11]. A L-galactosidase gene driven by SV40
early promoter was used in transfection and the L-galactosidase ac-
tivity was determined [12] as the internal control. All transfection
experiments were repeated at least three times and the pBLCAT3
with or without thymidine kinase promoter (TK) were used as positive
and negative control, respectively. The fAFP-CAT activity was ap-
proximately 25% in NBRK cells, 10% in HeLa cells and 4% of TK-
CAT activity in HepG2 cells.
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2.3. Gel retardation assay
Crude liver nuclear extract from male Sprague-Dawley rats (150^
200 g) was prepared as described by Gorski et al. [13]. The protein
concentration was approximately 8 Wg/Wl. Rat C/EBPK protein (pMal-
C/EBP) was expressed from pMal-C/EBP-CRI construct (rat C/EBPK
fused with maltose-binding protein, kindly provided by Dr. C. Muel-
ler, Queen’s University, Canada) by bacterial expression system. Sin-
gle-stranded oligonucleotides were annealed and end-labeled using
[Q-32P]ATP and polynucleotide kinase. In the binding reaction, rat
liver nuclear extract or bacterial expressed pMal-C/EBP was incu-
bated with unlabeled competitor DNA (as indicated) for 10 min in
binding bu¡er containing 25 mM HEPES, pH 8, 12.5 mM MgCl2,
20% glycerol, 25 mM KCl and 40 ng/Wl calf-thymus DNA. Then the
5P-end-labeled probe (15 000 cpm) was added and incubated for an-
other 20 min on ice. Free DNA and DNA-protein complexes were
resolved on 4% polyacrylamide gel in 20 mM Tris, 0.5 mM EDTA,
10 mM sodium acetate, pH 7.2. Double-stranded oligonucleotides
used as probes or competitors were as follows. OligoS: ATTTACA-
TAATGTTTTACATCAGCACTTCCTG; OligoB: ATAATGTTT-
CATCAGCACTT; AP1 consensus: CGCTTGATGACTCAGCCG-
GA [14] and C/EBP consensus: CTAGGCATATTGCGCAATATGC
[15]. All oligonucleotides were synthesized by the Biotechnology Serv-
ice Centre, Hospital for Sick Children, Toronto. Antibody speci¢c to
C/EBPK was purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA).
2.4. Site-directed mutagenesis
In vitro site-directed mutagenesis was performed by the method of
Deng and Nickolo¡ [16]. The wild-type In(192^350)5P-fAFP-CAT
plasmid was constructed as previously described [7]. The mutant
mIn(192^350)5P-fAFP-CAT was constructed using In(192^350)5P-
fAFP-CAT with a selective primer which converts the KpnI site into
BamHI site (ATCGATCCCCGGaTcCCGAGCTCTCGAAAT) and a
mutagenic primer which has a TA insertion in Element B (ATTTA-
CATAATGTTTtaCATCAGCACTACTTCCTG). The mutation was
con¢rmed by DNA sequencing.
3. Results
3.1. The skin-type AFP intron is homologous to the liver-type
AFP intron
To explore the di¡erent mechanisms controlling skin-type
and liver-type AFP gene expression, the gene organization of
a representative skin-type AFP gene, F2 [8], was compared
with the liver-type AFP gene (2A-7b) (Fig. 1). Despite their
distinct tissue expression patterns, the two types of AFPs had
similar gene structures with two exons and a single intron.
The sequence of the skin-type intron shared 95% identity
with the liver-type intron except that it contained an extra
241-bp insertion at position +254 [8]. The region of skin-
type intron corresponding to the Element B of the liver-type
intron was designated as Element S (Fig. 1) and interestingly,
a TA dinucleotide insertion was found within this element.
Since Element B was known to mediate the enhancer activity
of the liver-type intron [7], it is likely that there is a speci¢c
e¡ect for the presence of the TA insertion in Element S of the
skin-type AFP gene.
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Fig. 1. Comparison of the skin-type and liver-type AFP genes. The
approximate locations of the additional fragment are shown by
hatched box and Element S and B are shown by solid box and dot-
ted box, respectively. The asterisks indicate the gap in the DNA se-
quence. The ¢gure is not to scale.
Fig. 2. The skin-type intron is a ubiquitous enhancer. A: Schematic
illustration of the liver-type and the two skin-type constructs. The
constructs were transfected into NBRK (B) and HeLa (C) cells and
their activities normalized for transfection e⁄ciency using L-galacto-
sidase activity. The mean values and standard errors of the fold of
enhancement relative to the activity achieved with the fAFP-CAT
construct is shown.
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3.2. The intron of the skin-type AFP gene acts as a ubiquitous
enhancer
To study whether the skin-type intron, like the liver-type
intron, also has the transactivation activity, the F2In-fAFP-
CAT and RF2In-fAFP-CAT constructs which contain the
skin-type F2 intron in the natural or reverse orientation, re-
spectively, upstream of the fAFP-CAT, were constructed (Fig.
2A). The transient expression assay in NBRK revealed that
the F2In-fAFP-CAT exhibited a three fold enhancer activity
(Fig. 2B). However, the reversed F2 intron had little e¡ect on
transactivation, indicating that the enhancer activity might be
orientation dependent. The enhancer activity of the skin-type
intron was further tested in non-skin cells. Signi¢cant en-
hancer activity was also observed using the skin-type intron
in the HeLa (cervical carcinoma) cells (Fig. 2C). In contrast,
the liver-type intron exhibited no transactivation activity in
both NBRK and HeLa cells (Fig. 2B,C). Together, these stud-
ies suggested that the skin-type intron, like its homologous
liver-type intron, also functions as an enhancer. However,
the transactivation activity of the skin-type intron was more
widely distributed.
3.3. Element S of the skin-type intron does not interact with
C/EBPK
Since Element B of the liver-type intron is known to medi-
ate its liver-speci¢c enhancer activity, we speculated that the
TA insertion in Element S of the skin-type intron may alter its
transactivation ability and tissue speci¢city. First, gel retarda-
tion assays were carried out to investigate the interactions
between Element S and rat liver nuclear extract (Fig. 3A).
In the control experiment using Element B as probe (lanes
9^15), a speci¢c band was competed out by excess of unla-
beled Element B (lane 11) or the oligonucleotide containing
the C/EBP binding site (lane 13), and was supershifted by
antibody speci¢c to rat C/EBPK (lanes 14 and 15). In contrast,
though Element S was able to form DNA-protein complex
such as the AP1 complex with the rat liver extract, excess of
C/EBP consensus oligonucleotide was ine¡ective in competing
for binding with any of the complexes. Furthermore, none of
the complexes was recognized by antibody speci¢c for
C/EBPK (lanes 5^8). These data indicate that there is no in-
teraction between Element S and C/EBPK. To further examine
the C/EBPK binding speci¢city, rat C/EBPK protein (fused
with maltose binding protein) was also used in gel-shift assays
(Fig. 3B). The presence of recombinant C/EBPK protein was
veri¢ed using Western analysis with antibody speci¢c to
C/EBPK (data not shown). Using the liver-type Element B
as a probe, a shift was gradually formed with increasing
amounts of extract (lanes 2^4). This speci¢c band was com-
peted out by excess of cold Element B or C/EBP consensus
but not by AP1 consensus (lanes 5^7). On the other hand,
there was no speci¢c shift when Element S was used as probe
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Fig. 3. Element S does not interact with rat C/EBPK. Gel retardation assays were carried out with rat liver nuclear extract (A) or recombinant
rat C/EBPK (B). XS, molar excess of competitor; Ab, speci¢c antibody; NS, non-speci¢c antibody. Supershifted band is indicated by an aster-
isk.
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(lanes 9^11). Therefore, these results further con¢rm that El-
ement S of the skin-type gene does not interact with the liver-
enriched transcription factor C/EBPK.
3.4. The TA dinucleotide insertion in Element B of the liver-
type intron decreases its liver-speci¢c enhancer activity
To further study the e¡ect of Element S (that is, the TA
insertion to Element B) in transactivation, a mutated con-
struct, mIn(192^350)5P-fAFP-CAT, was generated by site-di-
rected mutagenesis to insert a TA dinucleotide directly into
the Element B sequence of the In(192^350)5P-fAFP-CAT con-
struct (Fig. 4A) [7]. Transient expression assays revealed that
the TA insertion dramatically decreased the enhancer activity
of the liver-type intron in HepG2 (human hepatoma) cells
(Fig. 4B). Moreover, the enhancer activity of these two con-
structs was examined in two non-liver cell lines (Fig. 4C).
Both the wild-type (WT) and the mutated (MT) constructs
exhibited no signi¢cant degree in transactivation activity in
HeLa and NBRK cells, implying that the sequences respon-
sible for skin-type intron activity may reside outside the +192
to +350 region. Together, these data suggested that the TA
dinucleotide insertion in Element S, which does not interact
with C/EBPK, diminishes the liver-speci¢c enhancer activity of
the skin-type intron. In contract, the interaction between ele-
ment B and C/EBPK mediates the liver-speci¢c enhancer ac-
tivity of the liver-type intron.
4. Discussion
Our study has demonstrated that the overall gene structure
of the skin-type AFP and the liver-type AFP is similar. The
major di¡erences between the only intron of the skin-type
AFP gene and the liver-type AFP gene include an insertion
of TA dinucleotide in the skin-type gene corresponding to
Element B of the liver-type gene and the presence of a 241-
bp large fragment in the skin-type AFP gene. Like the liver-
type intron, the skin-type AFP intron also exhibits enhancer
activity. However, its transactivation ability is ubiquitous,
which is consistent with the previous Northern analysis stud-
ies that the skin-type AFP mRNAs are widely distributed in
many tissues including skin, gill, ¢n, and scales, as well as
liver, stomach, intestine, kidney and spleen [6]. Transactiva-
tion of the skin-type intron was also observed in HepG2 cells
(data not shown). Therefore, it is believed that the intron of
the two AFP genes plays an important role in regulating their
di¡erential tissue distribution.
In addition, the observation of a TA insertion in the skin-
type intron was of particular interest because it is located in
the middle of Element B which is important for the enhancer
activity of the liver-type intron. The insertion e¡ectively de-
stroys the C/EBPK binding speci¢city, as demonstrated by
mobility shift assays using both the rat liver nuclear extract
and C/EBPK fusion protein. In the transfection studies, the
dinucleotide insertion in Element B of the liver-type intron
substantially reduced its expression in HepG2 cells, further
con¢rming the role of C/EBPK to its liver-speci¢c transacti-
vation ability. Since C/EBPK is present primarily in terminally
di¡erentiated cells such as hepatocytes and adipocytes [17],
the presence of the C/EBPK binding motif in Element B is
believed to mediate the liver-speci¢city of the liver-type AFP
intron, while the loss of the interaction to C/EBPK in Element
S might explain the broader tissue expression patterns of the
skin-type AFP mRNAs. The disruption of C/EBP binding site
has also been reported in the clotting factor IX promoter of
hemophilia B patients that signi¢cantly reduced its transacti-
vation activity [18]. Therefore, the participation of C/EBPK
and its disruption by naturally occuring mutation may be a
common mechanism in controlling di¡erential gene expression
in liver.
On the other hand, the additional 241-bp fragment in the
skin-type intron may also be involved in its transcriptional
regulation. It is possible that some other cis-acting sequences
in this skin-type fragment interact with transcription factor(s)
to dictate the skin-type AFP expression in external tissues. It
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Fig. 4. TA dinucleotide insertion of Element B destroys its liver-spe-
ci¢c enhancer activity. In(192-350)5P-fAFP-CAT (WT) and mutated
mIn(192-350)5P-fAFP-CAT (MT) (A) were transfected into HepG2
(B) as well as NBRK and HeLa (C) cells. The enhancement relative
to the activity achieved with the fAFP-CAT construct is shown.
The mean values and standard errors of three independent experi-
ments are given.
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is interesting to note that, similar to F2, the other skin-type
AFP genomic clone (11-3) shares common features including
an additional 288-bp fragment which is 97% identical to the
241-bp fragment in the F2 gene and the presence of Element S
in the corresponding region [8]. Sequences similar to GRE
and Oct-1 consensus binding site were found in these addi-
tional fragments of the skin-type AFP introns. The role of
these additional fragments and factors involved, if any, are
under investigation.
In addition to their distinct tissue distribution, the skin-type
and liver-type AFP mRNAs are di¡erentially regulated [5].
There is a 500^700-fold variation between the summer and
winter months of the liver-type mRNA and it is inhibited
by growth hormone. The skin-type AFP mRNA, on the other
hand, only exhibits a 10-fold seasonal variation and is refrac-
tory to growth hormone treatment. Whether this is mediated
by Element B and/or Element S and due to the £uctuation of
the C/EBPK and/or other mechanisms remains to be investi-
gated.
The presence of two distinct types of AFPs within a single
species is intriguing. The skin-type AFP is structurally very
similar to the liver-type but is signi¢cantly less active in ‘anti-
freeze’ activity [6]. However, whether the skin-type AFP con-
fers selective freeze protection to subcellular organelles or cell
milieu is unclear. Both the skin-type AFP and mRNA have
been localized to the winter £ounder gill cells (Murray et al.,
manuscript in preparation). It appears that the skin-type AFP
might o¡er the ¢rst line of defense against ice invasion.
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